In HIV+ patients, muscle mass measured as fat free mass index (FFMi = FFM/h2) in DXA has never been characterized in large epidemiological cohorts. We aimed: to describe the prevalence of low muscle mass using t- and z-score, per age decades, defined as <–2 SD from the mean FFMi for an Italian Caucasian population, respectively, for the same age or in the age strata 30 to 39 years; to identify predictors of FFMi change; and to assess the association between FFMi and all-cause mortality in a large HIV+ cohort.
Low Muscle Mass in HIV+ Patients: Prevalence, Predictors, and Clinical Implication / Guaraldi, Giovanni; Zona, Stefano; A., Silva; Orlando, Gabriella; Carli, Federica; A., Santoro; N., Crupi; Ligabue, Guido; Mussi, Chiara; L., Ferruci. - STAMPA. - na:(2012), pp. 409-409. ((Intervento presentato al convegno 19th Conference on Antiretroviruses and Opportunistic Infections tenutosi a Seattle nel 5-8 Mar 2012.
Low Muscle Mass in HIV+ Patients: Prevalence, Predictors, and Clinical Implication.
GUARALDI, Giovanni;ZONA, Stefano;ORLANDO, Gabriella;CARLI, FEDERICA;LIGABUE, Guido;MUSSI, Chiara;
2012-01-01
Abstract
In HIV+ patients, muscle mass measured as fat free mass index (FFMi = FFM/h2) in DXA has never been characterized in large epidemiological cohorts. We aimed: to describe the prevalence of low muscle mass using t- and z-score, per age decades, defined as <–2 SD from the mean FFMi for an Italian Caucasian population, respectively, for the same age or in the age strata 30 to 39 years; to identify predictors of FFMi change; and to assess the association between FFMi and all-cause mortality in a large HIV+ cohort.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
